Valeant Pharma (VRX) Said 'Very Close' on One or More Asset Sales

October 25, 2016 11:49 AM EDT

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Valeant Pharma (NYSE: VRX) is "very close" to announcing one or more asset sales and news could come before or with earnings on November 8th, according to a source.

Potential assets sales include Relistor, Australian unit Inova, dermatology units Obagi Medical and Solta, Provenge, Egyptian unit Amoun Pharma, and/or its Latin American operations.

The company's Bausch + Lomb unit, thought to be a sacred cow, was also put in play after CEO Joe Papa said in September it too could be sold.

Increased government scrutiny on pricing has been a sticking point in several of the sales, the source said.

The asset sales are a long time in the making and come as the company has been seeking to reduce complexity and lower its debt burden amid a sagging stock price and worries about liquidity.

Valeant is working with Goldman Sachs on the sale of several of the assets. Morgan Stanley is said to be assisting on other assets, including dermatology.

Valeant declined to comment.

Shares of Valeant are up 3.7% today.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Hot M&A, Mergers and Acquisitions, Rumors

Related Entities

Goldman Sachs, Morgan Stanley, Earnings

Add Your Comment